Currently, the GNPC has established the world’s largest neurodegenerative disease-focused proteomics data set for biomarker research, with 23 partners contributing nearly 35,000 analyzed biosamples and ~300 million protein measurements with matched and harmonized clinical data. This first version (V1) was released to the research community on July 15, 2025 on the AD Workbench and over 150 researchers have been granted access to date. Analyses of the V1 dataset have already demonstrated its utility in identifying molecular fingerprints across neurodegenerative disorders, including PD, Alzheimer’s Disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), and were recently featured in multiple publications in the Nature family of journals (https://www.nature.com/collections/ecegeajbhg).

The goal for this second cycle is to support data generation for at least 10,000 new samples completed on a minimum of these four assay platforms. The V1 dataset harmonized proteomics data predominantly from a single proteomic platform – the SomaScan 7k Assay, which was at the inception of the GNPC the widest proteomics platform available, and was the platform our founding partner Johnson & Johnson had already utilized for several large cohorts. This next cycle of the consortium will enhance the value of this resource by bringing together samples that have been analyzed on four complementary proteomics assays: Somalogic, Olink HT, NULISA CNS, and NULISA Inflammation Assays, further expanding and validating protein “hits”, and also bringing in additional landmark cohorts.